Pulse Biosciences Completes Enrollment in PRECISE-BTN Clinical Study

Pulse Biosciences, Inc. announced the completion of patient enrollment in its PRECISE-BTN clinical study, which evaluates the nPulse™ Vybrance™ Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study, initially designed for 50 patients, was expanded to 100 patients and enrolled participants across three U.S. clinical sites within approximately 12 months. The first patient enrolled has completed their 12-month follow-up visit. The study protocol includes follow-up at one, three, six, and twelve months post-procedure, with endpoints focusing on safety, nodule volume reduction, symptomatic relief, hormone normalization, and quality of life improvements. The company plans to present preliminary data at an upcoming medical conference.